Market Report

Life Science Research Tools Market Assessment 6th Edition (2019-2025)

November 7, 2022

73 pages


The sixth edition of this report provides an overview of the life sciences research tools (LSRT) market from 2019 to 2025. Life sciences research tools companies offer instruments, reagents and services to academic, biopharma, applied market, and (non-IVD) clinical customers. This market is consolidated, with top vendors including Agilent, Becton Dickinson, Danaher, Illumina, Merck-EMD Millipore, and Thermo Fisher representing the majority of sales; however,mid-size players (e.g., NanoString Technologies) and smaller emerging players(e.g., Vizgen, Quantum SI) are included in this report as well, as these companies grow rapidly.

As in previous versions, we carefully triangulated market growth with past and forecasted organic growth from keys players, many of which have experienced growth driven by acquisition. As a result, segmenting the market by technology,and taking a relatively conservative stance, we estimate that the life science research tools market will reach ~$74B in 2022, and is expected to grow ~7%p.a. in the next 3 years. We do believe that uncertainty to these forecast exist (potential range: 5-10% p.a.) considering the current macro economic environment, inflation and traction of many of these tools used for precision medicine, even though growth experienced due to the impact of COVID-19-relatedR&D is starting to slow down. However, long term guidance from top players tends to be in the mid-single digits, and conservative for historically fast-growing companies (e.g., 10% revenue growth guidance for Illumina in2023**). Our analysis confirms continued growth in emerging markets (e.g.,China) across customer segments, with additional funding in certain developed geographies (e.g., EU’s Horizon Europe, Biden Plan). This report evaluates which technologies are expected to capture (e.g., NGS, spatial omics) and lose(e.g., PCR) relative market share within their respective “omics” segments.

For each of these 36 subsegments, we present an analysis detailing sales of instruments and reagents for 2019, 2022, and 2025. In addition, we detail market drivers (e.g., increased government funding in some segments) and moderators (e.g., pricing pressure for some technologies), market trends (e.g.,interest in cell therapies, downstream use of liquid biopsy in oncology), a high-level end-customer breakdown (academic / gvt customers, biopharma / CROs,clinical non-IVD, and applied markets) and key competitors.

All data are based on manufacturer sales as publicly reported and DeciBio research and analysis*.

Pure Genomics Technologies

  • PCR
  • qPCR
  • Digital PCR
  • Microarrays
  • CE sequencing
  • NGS / 3GS
  • Molecular biology

Pure Proteomics Technologies

  • Western blot
  • Protein microarrays
  • Other immunoassays
  • Protein production
  • General antibodies

Pure Cell Biology Technologies

  • Flow cytometry
  • Whole cell analysis
  • High content imaging
  • Spatial omics
  • Microscopy
  • Cell culture equipment
  • Cells and tissues
  • Transfection and electroporation
  • Media and sera
  • Cell-based assay discovery services

Other Analytical Technologies

  • Chromatography
  • Mass spec
  • Structural analysis
  • In vivo study
  • Spectroscopy
  • Label-free technologies

Other Supplies and Technologies

  • Lab supplies and disposables
  • Lab automation
  • Glassware
  • Sample preparation
  • LIMS
  • Magnetic bead

Contact Us

Precision Medicine is evolving at a rapid pace

Discover how we can help

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.